Eisai to transfer North Carolina plant to Biogen

Published: 20-Jul-2015
Manufacturing

Biogen will continue to manufacture oral solid dose products for Eisai, in addition to parenteral products


Eisai has agreed to transfer ownership of its Research Triangle Park-based manufacturing facility in North Carolina, to Biogen.

The agreement expands a manufacturing alliance between the two companies concerning the North Carolina plant entered into in December 2012. Under this latest agreement, Eisai will transfer to Biogen the entire North Carolina plant, including the oral solid dose (OSD) facility, which was formerly leased by Biogen.

Biogen will continue to manufacture OSD products for Eisai after the expiration of the lease, in addition to parenteral products.

Approximately 100 Eisai employees will be offered jobs with Biogen when the deal closes in the second quarter.

After the transfer of manufacturing operations to Biogen, Eisai will continue to base supply chain management services in the Research Triangle Park area. In addition to maintaining global contract manufacturing management and quality assurance in North Carolina, production at the Baltimore plant in Maryland will continue unchanged to supply products for the US, as well as the global market.

  • Companies:
  • Biogen
  • Eisai
See more

You may also like

Manufacturing

Samsung Biologics acquires full ownership of Biogen joint venture

Read more
Biogen initially invested in a 15% stake in Samsung Bioepis when it was established as a joint venture in 2012

Trending Articles

  1. Sanofi invests €40m into biopharmaceutical manufacturing at its Lyon Gerland site The pharma giant has expanded its French monoclonal antibody production capabilities, while also dedicating €25m to the development of a second-gen polyclonal antibody
  2. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  3. Pharmaceutics International bolsters its prefilled syringe production capabilities The aseptic and oral dosage CDMO has invested USD $3.6m into advanced labelling, fill/finish and automated visual inspection technologies at its Hunt Valley site in Maryland, US
  4. Ardena's Oss nanomedicine facility gains full GMP approval from the Dutch Healthcare Authority The pharmaceutical manufacturing facility can produce advanced nanoparticle drug delivery systems, including lipid-based, polymeric and metal oxide nanoparticles
  5. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be complicated. Here, the tablet experts Natoli explain how to develop tabletability, compactibility, and compressibility profiles

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Manufacturing

Samsung Biologics acquires full ownership of Biogen joint venture

Biogen initially invested in a 15% stake in Samsung Bioepis when it was established as a joint venture in 2012
Manufacturing

Eisai and PharmStandard sign co-operation agreements in Russia

PharmStandard will handle important stages in the manufacturing of Eisai's oncology and epilepsy medicines
Manufacturing

Eisai opens new parenteral facility in China

To meet increased demand for injectable products and help cut costs
Manufacturing

Eisai opens new packaging facility in the UK to handle highly potent compounds

Located next to the company's current facility in Hatfield, Hertfordshire
Manufacturing

Eisai to expand global packaging facility in UK

Japanese firm will invest £8 million at its production plant in Hatfield, Hertfordshire to support the planned launch of several new products
Design & Build

Merck named Overall Winner in 2012 Facility of the Year Awards

For its vaccine bulk manufacturing facility (VBF) programme of projects in Durham, NC, US
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Looking ahead to a challenging year

Asia is emerging as a rival to the US as a leading source of drug discovery and high end innovation. Both clinical trials activity and investments by drug majors are set to expand in Asia, with India and China leading the charge. But the Indian, Chinese and Philippino governments are proposing to increase price controls on medicines, and lax intellectual property laws across the region could hinder growth.
Subscribe now